Payment overview · 2025
General Payments
$107.54
6 reported records · 5 companies
Healthcare provider profile · identity verified
James Ray Burleson, MD
Allopathic & Osteopathic Physicians|Obstetrics & Gynecology|Obstetrics · SNYDER, TX · NPI 1639134430
Verified facts
What the public records show
CMS Open Payments records show James Ray Burleson, MD received $107.54 in general payments during 2025 across 6 reported records.
Lilly USA, LLC accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.14 | 27.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.50 | 20.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $19.87 | 18.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.73 | 18.4% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $17.30 | 16.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $107.54 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.14 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.14 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 149 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
149 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 731 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 544 | 107 |
| Lisinopril | Lisinopril | 355 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 345 | 75 |
| Metformin Hcl | Metformin Hcl | 295 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 290 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 261 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 37 |
| Carvedilol | Carvedilol | 184 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 42 |
| Gabapentin | Gabapentin | 169 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 54 |
| Sertraline Hcl | Sertraline Hcl | 163 | 37 |
| Irbesartan | Irbesartan | 162 | 20 |
| Valsartan | Valsartan | 160 | 34 |
| Eliquis | Apixaban | 149 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 147 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 19 |
| Trazodone Hcl | Trazodone Hcl | 131 | 28 |
| Omeprazole | Omeprazole | 124 | 26 |
| Allopurinol | Allopurinol | 119 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 119 | 22 |
| Simvastatin | Simvastatin | 115 | 19 |
| Potassium Chloride | Potassium Chloride | 110 | 23 |
| Montelukast Sodium | Montelukast Sodium | 101 | 26 |
| Atenolol | Atenolol | 88 | 12 |
| Furosemide | Furosemide | 88 | 18 |
| Losartan Potassium | Losartan Potassium | 86 | 13 |
| Donepezil Hcl | Donepezil Hcl | 84 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 16 |
| Tramadol Hcl | Tramadol Hcl | 75 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 16 |
| Jardiance | Empagliflozin | 72 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 72 | 51 |
| Glipizide Er | Glipizide | 69 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 15 |
| Ozempic | Semaglutide | 68 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 11 |
| Mirtazapine | Mirtazapine | 67 | 12 |
| Farxiga | Dapagliflozin Propanediol | 65 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 14 |
| Nifedipine Er | Nifedipine | 58 | suppressed |
| Prednisone | Prednisone | 58 | 30 |
| Benazepril Hcl | Benazepril Hcl | 55 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | suppressed |
| Lansoprazole | Lansoprazole | 55 | suppressed |
| Primidone | Primidone | 52 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 51 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 34 |
| Azithromycin | Azithromycin | 49 | 37 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 38 |
| Glipizide | Glipizide | 42 | 11 |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Cephalexin | Cephalexin | 39 | 25 |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Indapamide | Indapamide | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | 11 |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Levemir | Insulin Detemir | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 14 |
| Paroxetine Er | Paroxetine Hcl | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Levofloxacin | Levofloxacin | 19 | 14 |
| Mupirocin | Mupirocin | 19 | 13 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $107.54 · 6 records | Lilly USA, LLC | ELIQUIS, GRAFIX PL, LEQVIO, MOUNJARO, NURTEC ODT, ZEPBOUND, ZURZUVAE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error